Anthera Pharmaceuticals 

We are focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.

Find out more about what we are doing for patients with Cystic Fibrosis and IgA Nephropathy:

Cystic Fibrosis
IgA Nephropathy
LATEST NEWS

Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network. Read more

Anthera Pharmaceuticals Announces FDA Orphan Designation for Blisibimod for the Treatment of IgA Nephropathy. Read more

Print Friendly